APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Disease

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neurodegenerative Disease Industry Growth and Trends Forecast to 2032

19 December 2025113 pages

Choose your research edition.

Industry ResearchNeurodegenerative Disease Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Disease Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Disease Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Disease Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

According to APO Research, the global Neurodegenerative Disease market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neurodegenerative Disease is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neurodegenerative Disease is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurodegenerative Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Neurodegenerative Disease market include Biogen Idec, Boehringer Ingelheim, Merck Serono, UCB, BORA PHARMACEUTICALS, Dongcheng Biochemicals, Ark Pharmaceutical, GlaxoSmithKline and Haisco Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neurodegenerative Disease market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neurodegenerative Disease market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neurodegenerative Disease market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neurodegenerative Disease.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Neurodegenerative Disease market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neurodegenerative Disease Market by Company

Biogen Idec

Boehringer Ingelheim

Merck Serono

UCB

BORA PHARMACEUTICALS

Dongcheng Biochemicals

Ark Pharmaceutical

GlaxoSmithKline

Haisco Pharmaceutical

Hisun Pharmaceutical

Huahai Pharmaceutical

Pfizer

Jingxin Pharmaceutical

Kanghong Pharmaceutical

Livzon Pharmaceutical

Luye Pharma

Novartis

Sanofi

TEVA

Neurodegenerative Disease Segment by Type

NMDA

SSRIs

Dopamine Inhibitors

Neurodegenerative Disease Segment by Application

Alzheimer’s Disease

Huntington Disease

Amyotrophic Lateral Sclerosis

Parkinson’s Disease

Neurodegenerative Disease Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Neurodegenerative Disease companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Neurodegenerative Disease Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Neurodegenerative Disease Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Neurodegenerative Disease Market Share by Region (2021-2026) Table 4. Global Neurodegenerative Disease Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Neurodegenerative Disease Market Share by Region (2027-2032) Table 6. Global Neurodegenerative Disease Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Neurodegenerative Disease Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Neurodegenerative Disease Market Size Share by Type (2021-2026) Table 9. Global Neurodegenerative Disease Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Neurodegenerative Disease Market Size Share Forecasted by Type (2027-2032) Table 11. North America Neurodegenerative Disease Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Neurodegenerative Disease Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Neurodegenerative Disease Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Neurodegenerative Disease Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Neurodegenerative Disease Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Neurodegenerative Disease Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Neurodegenerative Disease Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Neurodegenerative Disease Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Neurodegenerative Disease Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Neurodegenerative Disease Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Neurodegenerative Disease Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Neurodegenerative Disease Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Neurodegenerative Disease Market Size Share by Application (2021-2026) Table 24. Global Neurodegenerative Disease Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Neurodegenerative Disease Market Size Share Forecasted by Application (2027-2032) Table 26. North America Neurodegenerative Disease Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Neurodegenerative Disease Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Neurodegenerative Disease Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Neurodegenerative Disease Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Neurodegenerative Disease Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Neurodegenerative Disease Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Neurodegenerative Disease Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Neurodegenerative Disease Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Neurodegenerative Disease Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Neurodegenerative Disease Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Neurodegenerative Disease Industry Trends Table 37. Neurodegenerative Disease Industry Drivers Table 38. Neurodegenerative Disease Industry Opportunities and Challenges Table 39. Neurodegenerative Disease Industry Restraints Table 40. Global Neurodegenerative Disease Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Neurodegenerative Disease Revenue Market Share by Company (2021-2026) Table 42. Global Neurodegenerative Disease Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Neurodegenerative Disease Key Company Headquarters & Area Served Table 44. Global Neurodegenerative Disease Company, Product Type & Application Table 45. Global Neurodegenerative Disease Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Neurodegenerative Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Biogen Idec Company Information Table 49. Biogen Idec Business Overview Table 50. Biogen Idec Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Biogen Idec Neurodegenerative Disease Product Portfolio Table 52. Biogen Idec Recent Development Table 53. Boehringer Ingelheim Company Information Table 54. Boehringer Ingelheim Business Overview Table 55. Boehringer Ingelheim Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Boehringer Ingelheim Neurodegenerative Disease Product Portfolio Table 57. Boehringer Ingelheim Recent Development Table 58. Merck Serono Company Information Table 59. Merck Serono Business Overview Table 60. Merck Serono Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Merck Serono Neurodegenerative Disease Product Portfolio Table 62. Merck Serono Recent Development Table 63. UCB Company Information Table 64. UCB Business Overview Table 65. UCB Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. UCB Neurodegenerative Disease Product Portfolio Table 67. UCB Recent Development Table 68. BORA PHARMACEUTICALS Company Information Table 69. BORA PHARMACEUTICALS Business Overview Table 70. BORA PHARMACEUTICALS Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. BORA PHARMACEUTICALS Neurodegenerative Disease Product Portfolio Table 72. BORA PHARMACEUTICALS Recent Development Table 73. Dongcheng Biochemicals Company Information Table 74. Dongcheng Biochemicals Business Overview Table 75. Dongcheng Biochemicals Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Dongcheng Biochemicals Neurodegenerative Disease Product Portfolio Table 77. Dongcheng Biochemicals Recent Development Table 78. Ark Pharmaceutical Company Information Table 79. Ark Pharmaceutical Business Overview Table 80. Ark Pharmaceutical Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Ark Pharmaceutical Neurodegenerative Disease Product Portfolio Table 82. Ark Pharmaceutical Recent Development Table 83. GlaxoSmithKline Company Information Table 84. GlaxoSmithKline Business Overview Table 85. GlaxoSmithKline Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. GlaxoSmithKline Neurodegenerative Disease Product Portfolio Table 87. GlaxoSmithKline Recent Development Table 88. Haisco Pharmaceutical Company Information Table 89. Haisco Pharmaceutical Business Overview Table 90. Haisco Pharmaceutical Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Haisco Pharmaceutical Neurodegenerative Disease Product Portfolio Table 92. Haisco Pharmaceutical Recent Development Table 93. Hisun Pharmaceutical Company Information Table 94. Hisun Pharmaceutical Business Overview Table 95. Hisun Pharmaceutical Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Hisun Pharmaceutical Neurodegenerative Disease Product Portfolio Table 97. Hisun Pharmaceutical Recent Development Table 98. Huahai Pharmaceutical Company Information Table 99. Huahai Pharmaceutical Business Overview Table 100. Huahai Pharmaceutical Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Huahai Pharmaceutical Neurodegenerative Disease Product Portfolio Table 102. Huahai Pharmaceutical Recent Development Table 103. Pfizer Company Information Table 104. Pfizer Business Overview Table 105. Pfizer Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Pfizer Neurodegenerative Disease Product Portfolio Table 107. Pfizer Recent Development Table 108. Jingxin Pharmaceutical Company Information Table 109. Jingxin Pharmaceutical Business Overview Table 110. Jingxin Pharmaceutical Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Jingxin Pharmaceutical Neurodegenerative Disease Product Portfolio Table 112. Jingxin Pharmaceutical Recent Development Table 113. Kanghong Pharmaceutical Company Information Table 114. Kanghong Pharmaceutical Business Overview Table 115. Kanghong Pharmaceutical Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Kanghong Pharmaceutical Neurodegenerative Disease Product Portfolio Table 117. Kanghong Pharmaceutical Recent Development Table 118. Livzon Pharmaceutical Company Information Table 119. Livzon Pharmaceutical Business Overview Table 120. Livzon Pharmaceutical Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Livzon Pharmaceutical Neurodegenerative Disease Product Portfolio Table 122. Livzon Pharmaceutical Recent Development Table 123. Luye Pharma Company Information Table 124. Luye Pharma Business Overview Table 125. Luye Pharma Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Luye Pharma Neurodegenerative Disease Product Portfolio Table 127. Luye Pharma Recent Development Table 128. Novartis Company Information Table 129. Novartis Business Overview Table 130. Novartis Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Novartis Neurodegenerative Disease Product Portfolio Table 132. Novartis Recent Development Table 133. Sanofi Company Information Table 134. Sanofi Business Overview Table 135. Sanofi Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Sanofi Neurodegenerative Disease Product Portfolio Table 137. Sanofi Recent Development Table 138. TEVA Company Information Table 139. TEVA Business Overview Table 140. TEVA Neurodegenerative Disease Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. TEVA Neurodegenerative Disease Product Portfolio Table 142. TEVA Recent Development Table 143. North America Neurodegenerative Disease Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. North America Neurodegenerative Disease Market Size by Country (2021-2026) & (US$ Million) Table 145. North America Neurodegenerative Disease Market Share by Country (2021-2026) Table 146. North America Neurodegenerative Disease Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. North America Neurodegenerative Disease Market Share Forecast by Country (2027-2032) Table 148. Europe Neurodegenerative Disease Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Europe Neurodegenerative Disease Market Size by Country (2021-2026) & (US$ Million) Table 150. Europe Neurodegenerative Disease Market Share by Country (2021-2026) Table 151. Europe Neurodegenerative Disease Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Europe Neurodegenerative Disease Market Share Forecast by Country (2027-2032) Table 153. Asia-Pacific Neurodegenerative Disease Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Asia-Pacific Neurodegenerative Disease Market Size by Country (2021-2026) & (US$ Million) Table 155. Asia-Pacific Neurodegenerative Disease Market Share by Country (2021-2026) Table 156. Asia-Pacific Neurodegenerative Disease Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Asia-Pacific Neurodegenerative Disease Market Share Forecast by Country (2027-2032) Table 158. Latin America Neurodegenerative Disease Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Latin America Neurodegenerative Disease Market Size by Country (2021-2026) & (US$ Million) Table 160. Latin America Neurodegenerative Disease Market Share by Country (2021-2026) Table 161. Latin America Neurodegenerative Disease Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Latin America Neurodegenerative Disease Market Share Forecast by Country (2027-2032) Table 163. Middle East & Africa Neurodegenerative Disease Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Middle East & Africa Neurodegenerative Disease Market Size by Country (2021-2026) & (US$ Million) Table 165. Middle East & Africa Neurodegenerative Disease Market Share by Country (2021-2026) Table 166. Middle East & Africa Neurodegenerative Disease Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Middle East & Africa Neurodegenerative Disease Market Share Forecast by Country (2027-2032) Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Neurodegenerative Disease Product Image Figure 3. Global Neurodegenerative Disease Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Neurodegenerative Disease Market Size (2021-2032) & (US$ Million) Figure 5. Global Neurodegenerative Disease Market Share by Region: 2025 VS 2032 Figure 6. Global Neurodegenerative Disease Market Share by Region (2021-2032) Figure 7. North America Neurodegenerative Disease Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Neurodegenerative Disease Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Neurodegenerative Disease Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Neurodegenerative Disease Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Neurodegenerative Disease Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. NMDA Image Figure 13. Global NMDA Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. SSRIs Image Figure 15. Global SSRIs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Dopamine Inhibitors Image Figure 17. Global Dopamine Inhibitors Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Global Neurodegenerative Disease Market Size Overview by Type (2021-2032) & (US$ Million) Figure 19. Global Neurodegenerative Disease Market Share by Type 2025 VS 2032 Figure 20. North America Neurodegenerative Disease Market Size Share by Type (2021-2032) Figure 21. Europe Neurodegenerative Disease Market Size Share by Type (2021-2032) Figure 22. Asia-Pacific Neurodegenerative Disease Market Size Share by Type (2021-2032) Figure 23. Latin America Neurodegenerative Disease Market Size Share by Type (2021-2032) Figure 24. Middle East and Africa Neurodegenerative Disease Market Size Share by Type (2021-2032) Figure 25. Alzheimer’s Disease Image Figure 26. Global Alzheimer’s Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Huntington Disease Image Figure 28. Global Huntington Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Amyotrophic Lateral Sclerosis Image Figure 30. Global Amyotrophic Lateral Sclerosis Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Parkinson’s Disease Image Figure 32. Global Parkinson’s Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Neurodegenerative Disease Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Neurodegenerative Disease Market Share by Application 2025 VS 2032 Figure 35. North America Neurodegenerative Disease Market Size Share by Application (2021-2032) Figure 36. Europe Neurodegenerative Disease Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Neurodegenerative Disease Market Size Share by Application (2021-2032) Figure 38. Latin America Neurodegenerative Disease Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Neurodegenerative Disease Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Neurodegenerative Disease Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Neurodegenerative Disease Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Neurodegenerative Disease Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Neurodegenerative Disease Market Share by Country (2021-2032) Figure 45. Europe Neurodegenerative Disease Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Neurodegenerative Disease Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Neurodegenerative Disease Market Share by Country (2021-2032) Figure 48. Asia-Pacific Neurodegenerative Disease Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Neurodegenerative Disease Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Neurodegenerative Disease Market Share by Country (2021-2032) Figure 51. Latin America Neurodegenerative Disease Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Neurodegenerative Disease Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Neurodegenerative Disease Market Share by Country (2021-2032) Figure 54. Middle East & Africa Neurodegenerative Disease Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Neurodegenerative Disease Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Neurodegenerative Disease Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • NMDA
  • SSRIs
  • Dopamine Inhibitors
Applications
  • Alzheimer’s Disease
  • Huntington Disease
  • Amyotrophic Lateral Sclerosis
  • Parkinson’s Disease
Companies covered
  • Biogen Idec
  • Boehringer Ingelheim
  • Merck Serono
  • UCB
  • BORA PHARMACEUTICALS
  • Dongcheng Biochemicals
  • Ark Pharmaceutical
  • GlaxoSmithKline
  • Haisco Pharmaceutical
  • Hisun Pharmaceutical
  • Huahai Pharmaceutical
  • Pfizer
  • Jingxin Pharmaceutical
  • Kanghong Pharmaceutical
  • Livzon Pharmaceutical
  • Luye Pharma
  • Novartis
  • Sanofi
  • TEVA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Neurodegenerative Disease Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Neurodegenerative Disease Market Size by Region (2021-2032)
  5. 1.4.1 Global Neurodegenerative Disease Market Size by Region (2021-2026)
  6. 1.4.2 Global Neurodegenerative Disease Market Size by Region (2027-2032)
  7. 1.5 Key Regions Neurodegenerative Disease Market Size (2021-2032)
  8. 1.5.1 North America Neurodegenerative Disease Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Neurodegenerative Disease Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Neurodegenerative Disease Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Neurodegenerative Disease Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Neurodegenerative Disease Market Size Growth Rate (2021-2032)
2 Neurodegenerative Disease Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 NMDA
  3. 2.1.2 SSRIs
  4. 2.1.3 Dopamine Inhibitors
  5. 2.2 Global Neurodegenerative Disease Market Size by Type
  6. 2.2.1 Global Neurodegenerative Disease Market Size Overview by Type (2021-2032)
  7. 2.2.2 Global Neurodegenerative Disease Historic Market Size Review by Type (2021-2026)
  8. 2.2.3 Global Neurodegenerative Disease Market Size Forecasted by Type (2027-2032)
  9. 2.3 Global Neurodegenerative Disease Market Size by Regions
  10. 2.3.1 North America Neurodegenerative Disease Market Size Breakdown by Type (2021-2026)
  11. 2.3.2 Europe Neurodegenerative Disease Market Size Breakdown by Type (2021-2026)
  12. 2.3.3 Asia-Pacific Neurodegenerative Disease Market Size Breakdown by Type (2021-2026)
  13. 2.3.4 South America Neurodegenerative Disease Market Size Breakdown by Type (2021-2026)
  14. 2.3.5 Middle East and Africa Neurodegenerative Disease Market Size Breakdown by Type (2021-2026)
3 Neurodegenerative Disease Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Alzheimer’s Disease
  3. 3.1.2 Huntington Disease
  4. 3.1.3 Amyotrophic Lateral Sclerosis
  5. 3.1.4 Parkinson’s Disease
  6. 3.2 Global Neurodegenerative Disease Market Size by Application
  7. 3.2.1 Global Neurodegenerative Disease Market Size Overview by Application (2021-2032)
  8. 3.2.2 Global Neurodegenerative Disease Historic Market Size Review by Application (2021-2026)
  9. 3.2.3 Global Neurodegenerative Disease Market Size Forecasted by Application (2027-2032)
  10. 3.3 Global Neurodegenerative Disease Market Size by Regions
  11. 3.3.1 North America Neurodegenerative Disease Market Size Breakdown by Application (2021-2026)
  12. 3.3.2 Europe Neurodegenerative Disease Market Size Breakdown by Application (2021-2026)
  13. 3.3.3 Asia-Pacific Neurodegenerative Disease Market Size Breakdown by Application (2021-2026)
  14. 3.3.4 South America Neurodegenerative Disease Market Size Breakdown by Application (2021-2026)
  15. 3.3.5 Middle East and Africa Neurodegenerative Disease Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Neurodegenerative Disease Industry Trends
  2. 4.2 Neurodegenerative Disease Industry Drivers
  3. 4.3 Neurodegenerative Disease Industry Opportunities and Challenges
  4. 4.4 Neurodegenerative Disease Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Neurodegenerative Disease Revenue (2021-2026)
  2. 5.2 Global Neurodegenerative Disease Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Neurodegenerative Disease Key Company Headquarters & Area Served
  4. 5.4 Global Neurodegenerative Disease Company, Product Type & Application
  5. 5.5 Global Neurodegenerative Disease Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Neurodegenerative Disease Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Neurodegenerative Disease Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Neurodegenerative Disease Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Biogen Idec
  2. 6.1.1 Biogen Idec Company Information
  3. 6.1.2 Biogen Idec Business Overview
  4. 6.1.3 Biogen Idec Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Biogen Idec Neurodegenerative Disease Product Portfolio
  6. 6.1.5 Biogen Idec Recent Developments
  7. 6.2 Boehringer Ingelheim
  8. 6.2.1 Boehringer Ingelheim Company Information
  9. 6.2.2 Boehringer Ingelheim Business Overview
  10. 6.2.3 Boehringer Ingelheim Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Boehringer Ingelheim Neurodegenerative Disease Product Portfolio
  12. 6.2.5 Boehringer Ingelheim Recent Developments
  13. 6.3 Merck Serono
  14. 6.3.1 Merck Serono Company Information
  15. 6.3.2 Merck Serono Business Overview
  16. 6.3.3 Merck Serono Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Merck Serono Neurodegenerative Disease Product Portfolio
  18. 6.3.5 Merck Serono Recent Developments
  19. 6.4 UCB
  20. 6.4.1 UCB Company Information
  21. 6.4.2 UCB Business Overview
  22. 6.4.3 UCB Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 UCB Neurodegenerative Disease Product Portfolio
  24. 6.4.5 UCB Recent Developments
  25. 6.5 BORA PHARMACEUTICALS
  26. 6.5.1 BORA PHARMACEUTICALS Company Information
  27. 6.5.2 BORA PHARMACEUTICALS Business Overview
  28. 6.5.3 BORA PHARMACEUTICALS Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 BORA PHARMACEUTICALS Neurodegenerative Disease Product Portfolio
  30. 6.5.5 BORA PHARMACEUTICALS Recent Developments
  31. 6.6 Dongcheng Biochemicals
  32. 6.6.1 Dongcheng Biochemicals Company Information
  33. 6.6.2 Dongcheng Biochemicals Business Overview
  34. 6.6.3 Dongcheng Biochemicals Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Dongcheng Biochemicals Neurodegenerative Disease Product Portfolio
  36. 6.6.5 Dongcheng Biochemicals Recent Developments
  37. 6.7 Ark Pharmaceutical
  38. 6.7.1 Ark Pharmaceutical Company Information
  39. 6.7.2 Ark Pharmaceutical Business Overview
  40. 6.7.3 Ark Pharmaceutical Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Ark Pharmaceutical Neurodegenerative Disease Product Portfolio
  42. 6.7.5 Ark Pharmaceutical Recent Developments
  43. 6.8 GlaxoSmithKline
  44. 6.8.1 GlaxoSmithKline Company Information
  45. 6.8.2 GlaxoSmithKline Business Overview
  46. 6.8.3 GlaxoSmithKline Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 GlaxoSmithKline Neurodegenerative Disease Product Portfolio
  48. 6.8.5 GlaxoSmithKline Recent Developments
  49. 6.9 Haisco Pharmaceutical
  50. 6.9.1 Haisco Pharmaceutical Company Information
  51. 6.9.2 Haisco Pharmaceutical Business Overview
  52. 6.9.3 Haisco Pharmaceutical Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Haisco Pharmaceutical Neurodegenerative Disease Product Portfolio
  54. 6.9.5 Haisco Pharmaceutical Recent Developments
  55. 6.10 Hisun Pharmaceutical
  56. 6.10.1 Hisun Pharmaceutical Company Information
  57. 6.10.2 Hisun Pharmaceutical Business Overview
  58. 6.10.3 Hisun Pharmaceutical Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Hisun Pharmaceutical Neurodegenerative Disease Product Portfolio
  60. 6.10.5 Hisun Pharmaceutical Recent Developments
  61. 6.11 Huahai Pharmaceutical
  62. 6.11.1 Huahai Pharmaceutical Company Information
  63. 6.11.2 Huahai Pharmaceutical Business Overview
  64. 6.11.3 Huahai Pharmaceutical Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Huahai Pharmaceutical Neurodegenerative Disease Product Portfolio
  66. 6.11.5 Huahai Pharmaceutical Recent Developments
  67. 6.12 Pfizer
  68. 6.12.1 Pfizer Company Information
  69. 6.12.2 Pfizer Business Overview
  70. 6.12.3 Pfizer Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Pfizer Neurodegenerative Disease Product Portfolio
  72. 6.12.5 Pfizer Recent Developments
  73. 6.13 Jingxin Pharmaceutical
  74. 6.13.1 Jingxin Pharmaceutical Company Information
  75. 6.13.2 Jingxin Pharmaceutical Business Overview
  76. 6.13.3 Jingxin Pharmaceutical Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Jingxin Pharmaceutical Neurodegenerative Disease Product Portfolio
  78. 6.13.5 Jingxin Pharmaceutical Recent Developments
  79. 6.14 Kanghong Pharmaceutical
  80. 6.14.1 Kanghong Pharmaceutical Company Information
  81. 6.14.2 Kanghong Pharmaceutical Business Overview
  82. 6.14.3 Kanghong Pharmaceutical Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Kanghong Pharmaceutical Neurodegenerative Disease Product Portfolio
  84. 6.14.5 Kanghong Pharmaceutical Recent Developments
  85. 6.15 Livzon Pharmaceutical
  86. 6.15.1 Livzon Pharmaceutical Company Information
  87. 6.15.2 Livzon Pharmaceutical Business Overview
  88. 6.15.3 Livzon Pharmaceutical Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Livzon Pharmaceutical Neurodegenerative Disease Product Portfolio
  90. 6.15.5 Livzon Pharmaceutical Recent Developments
  91. 6.16 Luye Pharma
  92. 6.16.1 Luye Pharma Company Information
  93. 6.16.2 Luye Pharma Business Overview
  94. 6.16.3 Luye Pharma Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Luye Pharma Neurodegenerative Disease Product Portfolio
  96. 6.16.5 Luye Pharma Recent Developments
  97. 6.17 Novartis
  98. 6.17.1 Novartis Company Information
  99. 6.17.2 Novartis Business Overview
  100. 6.17.3 Novartis Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Novartis Neurodegenerative Disease Product Portfolio
  102. 6.17.5 Novartis Recent Developments
  103. 6.18 Sanofi
  104. 6.18.1 Sanofi Company Information
  105. 6.18.2 Sanofi Business Overview
  106. 6.18.3 Sanofi Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Sanofi Neurodegenerative Disease Product Portfolio
  108. 6.18.5 Sanofi Recent Developments
  109. 6.19 TEVA
  110. 6.19.1 TEVA Company Information
  111. 6.19.2 TEVA Business Overview
  112. 6.19.3 TEVA Neurodegenerative Disease Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 TEVA Neurodegenerative Disease Product Portfolio
  114. 6.19.5 TEVA Recent Developments
7 North America
  1. 7.1 North America Neurodegenerative Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Neurodegenerative Disease Market Size by Country (2021-2026)
  3. 7.3 North America Neurodegenerative Disease Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Neurodegenerative Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Neurodegenerative Disease Market Size by Country (2021-2026)
  3. 8.3 Europe Neurodegenerative Disease Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Neurodegenerative Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Neurodegenerative Disease Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Neurodegenerative Disease Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Neurodegenerative Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Neurodegenerative Disease Market Size by Country (2021-2026)
  3. 10.3 South America Neurodegenerative Disease Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Neurodegenerative Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Neurodegenerative Disease Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Neurodegenerative Disease Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst